PLSE logo

Pulse Biosciences (PLSE) News & Sentiment

Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025
Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025
Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025
PLSE
businesswire.comMarch 7, 2025

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, March 27, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by.

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
PLSE
businesswire.comDecember 23, 2024

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about December 27, 2024, to redeem the first tranche of common stock warrants, redeemable by the Company if the Company's stock trading price exceeds $16.50 for twenty consecutive trading days, that were issued as part of its.

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants
Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants
Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants
PLSE
businesswire.comDecember 19, 2024

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that, on December 18, 2024, the Company's Co-Chairman and majority shareholder, Robert W. Duggan, exercised all of the warrants he acquired in the Company's 2024 rights offering, corresponding to $58.4 million totaling to 5,306,156 shares of Co.

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association
Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association
Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association
PLSE
businesswire.comOctober 31, 2024

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation for the treatment of benign thyroid nodules. Dr. Stefano Spiezia presented these excellent results today at the 2024 American Thyroid Association Annual Meeting. The preliminary data demonstrate.

Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript
Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript
Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript
PLSE
seekingalpha.comAugust 12, 2024

Pulse Biosciences Inc. (NASDAQ:PLSE ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Philip Taylor - Investor Relations Burke Barrett - President & CEO Michael Koffler - VP of Finance Conference Call Participants Anthony Petrone - Mizuho Group Operator Greetings, and welcome to the Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Pulse Biosciences, Inc. (NASDAQ: PLSE)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Pulse Biosciences, Inc. (NASDAQ: PLSE)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Pulse Biosciences, Inc. (NASDAQ: PLSE)
PLSE
prnewswire.comAugust 1, 2024

NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Pulse Biosciences, Inc. (NASDAQ: PLSE) on behalf of the company's shareholders. The investigation seeks to determine whether Pulse Bioscience's directors breached their fiduciary duties in connection with recent corporate actions.

Pulse Biosciences, Inc. (PLSE) Q3 2023 Earnings Call Transcript
Pulse Biosciences, Inc. (PLSE) Q3 2023 Earnings Call Transcript
Pulse Biosciences, Inc. (PLSE) Q3 2023 Earnings Call Transcript
PLSE
Seeking AlphaNovember 13, 2023

Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q3 2023 Earnings Conference Call November 13, 2023 12:00 PM ET Company Participants Philip Taylor - IR Kevin Danahy - President and CEO Darrin Uecker - CTO and Director Mitchell Levinson - Chief Strategy Officer Michael Koffler - VP of Finance Bob Duggan - Chairman Conference Call Participants Operator Greetings, and welcome to the Pulse Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call
UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call
UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call
PLSE
Business WireNovember 10, 2023

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced it will now report financial results for the third quarter of 2023 before market opens on Monday, November 13, 2023. Company management will now host a corresponding conference call beginning at 9:00am PT / 12:00pm ET. Invest.

Pulse Biosciences Inc. (PLSE) Q2 2023 Earnings Call Transcript
Pulse Biosciences Inc. (PLSE) Q2 2023 Earnings Call Transcript
Pulse Biosciences Inc. (PLSE) Q2 2023 Earnings Call Transcript
PLSE
Seeking AlphaAugust 10, 2023

Pulse Biosciences Inc. (NASDAQ:PLSE ) Q2 2023 Results Conference Call August 10, 2023 4:30 PM ET Company Participants Philip Taylor - IR Kevin Danahy - Chief Executive Officer Darrin Uecker - CTO & Director Mitchell Levinson - Chief Strategy Officer Michael Koffler - Director of Finance Bob Duggan - Chariman of the Board of Pulse Biosciences Operator Greetings, and welcome to Pulse Biosciences' Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Pulse Biosciences, Inc. (PLSE) Q1 2023 Earnings Call Transcript
Pulse Biosciences, Inc. (PLSE) Q1 2023 Earnings Call Transcript
Pulse Biosciences, Inc. (PLSE) Q1 2023 Earnings Call Transcript
PLSE
Seeking AlphaMay 11, 2023

Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Trip Taylor - Investor Relations Kevin Danahy - President & Chief Executive Officer Darrin Uecker - Chief Technology Officer Mike Koffler - Vice President of Finance Robert Duggan – Executive Chairman Conference Call Participants Robert Lovgren – Medical Hope Productions Operator Good afternoon, ladies and gentlemen and thank you for standing by. Welcome to the Pulse Biosciences First Quarter 2023 Earnings Conference Call.

  • 1(current)
  • 2
  • 1(current)
  • 2